Activation of the epidermal growth factor receptor (EGFR) is closely linked to the physiology and pathophysiology of the cardiovascular system, and inhibition of EGFR activity is emerging as a potential therapeutic strategy for the treatment of diseases such as hypertension, cardiac hypertrophy, renal fibrosis, and abdominal aortic aneurysms [23]. Here, EGFR is linked to renal fibrosis.